MorphoSys Starts Multiple Antibody Programs with Schering
News Oct 11, 2005
MorphoSys AG has announced the start of a further three therapeutic antibody programs within the scope of its collaboration with Schering AG, Germany.
Schering has selected three target molecules, against which MorphoSys will generate antibodies using its proprietary HuCAL GOLD® technology.
Additionally, MorphoSys has granted Schering eight exclusive licenses for in vivo diagnostic applications. In exchange, MorphoSys stands to receive licensing payments.
Schering will carry out pre-clinical and clinical development and has the worldwide marketing rights for all resulting products.
Within the collaboration, originally signed in December 2001, both companies develop antibodies against a variety of disease-related target molecules mainly involved in oncology for both therapeutic and in vivo diagnostic purposes.
The collaboration was extended in December 2004 until the end of 2006, with the option of a further extension period of one year beyond this time frame.
Including this announcement, the parties have six therapeutic antibody programs based on MorphoSys's HuCAL® technology currently in progress. Schering owns approximately 6% of outstanding shares of MorphoSys.
“Partnered programs based on our HuCAL® technology in which we participate through milestone and royalty payments have always been at the center of the MorphoSys strategy,” explained Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG.
“Combined with these new programs with our partner Schering there are currently more than 25 partnered programs ongoing, and as these move forward, the frequency and size of milestone payments will further increase.”
Restoring the ability to walk following spinal cord injury requires neurons in the brain to reestablish communication pathways with neurons in the spinal cord, Mature neurons, however, are unable to regenerate their axons to facilitate this process. New research in mice shows one potential route to overcome this limitation may be by targeting liver kinase B1 (LKB1) protein.
International Conference on Cell and Structural biology
Jul 15 - Jul 16, 2019